Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navarixin + Pembrolizumab in Advanced Solid Tumors
NCT03473925Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2018
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of navarixin in non-small cell lung cancer (NSCLC), prostate cancer (PCa) and colorectal cancer (CRC) (2 arms), sponsored by Merck & Co. Primary endpoints: Objective Response Rate, Number of Participants With Dose-limiting Toxicities up to 21 days and 2 more. Started Apr 2018; status: completed.
02
Drugs
navarixin
03
Conditions
non-small cell lung cancer (NSCLC)prostate cancer (PCa)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03473925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03473925.